Denali Therapeutics' innovative approach to neurological disorders and strong financial strategy position it as a leader in ...

Anxious and bewildered, some drugmakers are reaching out to their lobbyists about how Robert Kennedy’s pending nomination ...

MNKD-201, an inhaled formulation of nintedanib for IPF, was shown to be safe and well tolerated in a clinical trial with ...

Donald Trump's pick for head of Health and Human Services is trying to walk back his anti-vaxxer past — but still sowing ...

Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...

Robert F. Kennedy Jr., Trump's pick​ to lead the Department of Health and Human Services, has raised controversy on topics ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a new study.

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 ...

Q3 2024 Earnings Call Transcript November 15, 2024 Operator: Hello, and welcome to the AIM ImmunoTech Third Quarter 2024 ...

A possible breakthrough has been made in slowing the effects of Alzheimer’s in the form of a drug currently undergoing ...

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...